# Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)

> **NCT01156415** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 837 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** AGO178
- **DRUG:** AGO178

## Key facts

- **NCT ID:** NCT01156415
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-06
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 837 (ACTUAL)
- **Last updated:** 2020-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01156415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01156415, "Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01156415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*